CO2023000156A2 - Administración de vectores de virus adenoasociado para distrofias musculares - Google Patents
Administración de vectores de virus adenoasociado para distrofias muscularesInfo
- Publication number
- CO2023000156A2 CO2023000156A2 CONC2023/0000156A CO2023000156A CO2023000156A2 CO 2023000156 A2 CO2023000156 A2 CO 2023000156A2 CO 2023000156 A CO2023000156 A CO 2023000156A CO 2023000156 A2 CO2023000156 A2 CO 2023000156A2
- Authority
- CO
- Colombia
- Prior art keywords
- adeno
- associated virus
- virus vector
- muscular dystrophies
- vector administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
La descripción proporciona un método para tratar la distrofia muscular, en un sujeto que lo necesita, que comprende la administración de un vector de terapia génica, como un vector de virus adenoasociado (AAV), que expresa un gen de microdistrofina humana miniaturizada en combinación con una etapa de supresión del sistema inmunitario del sujeto.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063039252P | 2020-06-15 | 2020-06-15 | |
US202063083953P | 2020-09-27 | 2020-09-27 | |
US202163160376P | 2021-03-12 | 2021-03-12 | |
US202163188266P | 2021-05-13 | 2021-05-13 | |
PCT/US2021/037470 WO2021257595A1 (en) | 2020-06-15 | 2021-06-15 | Adeno-associated virus vector delivery for muscular dystrophies |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023000156A2 true CO2023000156A2 (es) | 2023-03-27 |
Family
ID=77051123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0000156A CO2023000156A2 (es) | 2020-06-15 | 2023-01-10 | Administración de vectores de virus adenoasociado para distrofias musculares |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210393801A1 (es) |
EP (1) | EP4164668A1 (es) |
JP (1) | JP2023530974A (es) |
KR (1) | KR20230035043A (es) |
CN (1) | CN116348149A (es) |
AU (1) | AU2021293197A1 (es) |
BR (1) | BR112022025586A2 (es) |
CA (1) | CA3187353A1 (es) |
CO (1) | CO2023000156A2 (es) |
IL (1) | IL299094A (es) |
MX (1) | MX2022016332A (es) |
TW (1) | TW202208630A (es) |
WO (1) | WO2021257595A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018071167A2 (pt) * | 2016-04-15 | 2019-02-05 | Research Institute At Nationwide Children's Hospital | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular |
WO2024006855A1 (en) * | 2022-06-30 | 2024-01-04 | Sarepta Therapeutics, Inc. | Methods of treating muscular dystrophy |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
AU688428B2 (en) | 1993-11-09 | 1998-03-12 | Johns Hopkins University, The | Generation of high titers of recombinant AAV vectors |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
EP0850313B8 (en) | 1995-09-08 | 2009-07-29 | Genzyme Corporation | Improved aav vectors for gene therapy |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
DE69738351T2 (de) | 1996-09-06 | 2008-11-13 | The Trustees Of The University Of Pennsylvania | Verfaheren zur durch rekombinante adeno-assoziierte virus-gerichtete gentherapie |
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
ES2399232T3 (es) | 1997-09-05 | 2013-03-26 | Genzyme Corporation | Procedimientos para la generación de preparaciones de vectores de AAV recombinantes de títulos altos exentas de auxiliares |
DE69936444T3 (de) | 1998-02-03 | 2012-05-10 | Protiva Biotherapeutics Inc. | Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター |
WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
EP2567693B1 (en) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering RNA |
US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
AU2004272646B2 (en) | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
US9149564B2 (en) | 2006-06-23 | 2015-10-06 | The Regents Of The University Of California | Articles comprising large-surface-area bio-compatible materials and methods for making and using them |
EP2224912B1 (en) | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
NO2355851T3 (es) | 2008-11-10 | 2018-09-01 | ||
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
IL292615B2 (en) | 2009-07-01 | 2023-11-01 | Protiva Biotherapeutics Inc | Nucleic acid-lipid particles, preparations containing them and their uses |
WO2011004395A1 (en) | 2009-07-06 | 2011-01-13 | Intas Biopharmaceuticals Limited | Microemulsion formulation for biologicals |
WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
US9687550B2 (en) | 2009-12-07 | 2017-06-27 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
EP2512449B1 (en) | 2009-12-18 | 2019-08-07 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
AU2011252005B2 (en) | 2010-05-10 | 2014-07-24 | The Regents Of The University Of California | Ratiometric combinatorial drug delivery |
JP2013527856A (ja) | 2010-05-12 | 2013-07-04 | プロチバ バイオセラピューティクス インコーポレイティッド | 陽イオン性脂質およびその使用方法 |
CA2800401C (en) | 2010-06-03 | 2020-09-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
WO2013016126A1 (en) | 2011-07-22 | 2013-01-31 | The General Hospital Corporation | Therapeutic nanoparticles and methods of use thereof |
EP3290055A3 (en) | 2011-07-25 | 2018-05-30 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
AU2012347605B2 (en) | 2011-12-07 | 2017-09-21 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
DE21212055T1 (de) | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
US9415109B2 (en) | 2012-07-06 | 2016-08-16 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
KR101890951B1 (ko) | 2012-12-20 | 2018-08-22 | 에스케이이노베이션 주식회사 | 합성 가스 및 고품위 석탄의 동시 생산을 위한 건조 및 가스화 통합 공정 |
JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
EP3245291A4 (en) | 2015-01-16 | 2018-09-19 | University of Washington | Novel micro-dystrophins and related methods of use |
IL283545B2 (en) | 2015-06-29 | 2023-09-01 | Acuitas Therapeutics Inc | Lipids and nanoparticulate lipid formulations for delivery of nucleic acids |
PT3368507T (pt) | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
KR20180081566A (ko) | 2015-11-12 | 2018-07-16 | 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 근이영양증을 치료하는 방법 |
EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
MA45477A (fr) * | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
CA2971303A1 (en) * | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
CN107369008A (zh) | 2017-07-17 | 2017-11-21 | 北京京东金融科技控股有限公司 | 用于提高票据交易安全性的管理方法、装置及*** |
EP3697915A4 (en) * | 2017-10-18 | 2021-12-08 | Research Institute at Nationwide Children's Hospital | ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
CN111818946A (zh) * | 2018-01-31 | 2020-10-23 | 国家儿童医院研究所 | 2c型肢带型肌营养不良的基因疗法 |
WO2019177550A1 (en) | 2018-03-10 | 2019-09-19 | Koc Universitesi | Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same |
CN111971050A (zh) | 2018-04-03 | 2020-11-20 | 密苏里大学管理机构 | 用于抗肌萎缩蛋白病治疗的铰链1和/或4修饰的抗肌萎缩蛋白 |
US20210163939A1 (en) | 2018-04-23 | 2021-06-03 | The Curators Of The University Of Missouri | Improved crispr therapy |
BR112020025995A2 (pt) * | 2018-06-18 | 2021-03-23 | Research Institute At Nationwide Children's Hospital | administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular |
MX2020014119A (es) | 2018-06-29 | 2021-06-18 | Res Inst Nationwide Childrens Hospital | Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a. |
AU2019361129A1 (en) | 2018-10-18 | 2021-05-20 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
WO2020123645A1 (en) | 2018-12-12 | 2020-06-18 | Solid Biosciences Inc. | Combination therapy for treating muscular dystrophy |
CA3131390A1 (en) | 2019-02-26 | 2020-09-03 | Research Institute Of Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy |
-
2021
- 2021-06-15 US US17/348,515 patent/US20210393801A1/en active Pending
- 2021-06-15 TW TW110121662A patent/TW202208630A/zh unknown
- 2021-06-15 JP JP2022577296A patent/JP2023530974A/ja active Pending
- 2021-06-15 CA CA3187353A patent/CA3187353A1/en active Pending
- 2021-06-15 WO PCT/US2021/037470 patent/WO2021257595A1/en active Application Filing
- 2021-06-15 IL IL299094A patent/IL299094A/en unknown
- 2021-06-15 EP EP21746204.3A patent/EP4164668A1/en active Pending
- 2021-06-15 CN CN202180055748.XA patent/CN116348149A/zh active Pending
- 2021-06-15 MX MX2022016332A patent/MX2022016332A/es unknown
- 2021-06-15 BR BR112022025586A patent/BR112022025586A2/pt unknown
- 2021-06-15 KR KR1020237001636A patent/KR20230035043A/ko unknown
- 2021-06-15 AU AU2021293197A patent/AU2021293197A1/en active Pending
-
2023
- 2023-01-10 CO CONC2023/0000156A patent/CO2023000156A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3187353A1 (en) | 2021-12-23 |
MX2022016332A (es) | 2023-04-03 |
TW202208630A (zh) | 2022-03-01 |
CN116348149A (zh) | 2023-06-27 |
EP4164668A1 (en) | 2023-04-19 |
BR112022025586A2 (pt) | 2023-03-07 |
US20210393801A1 (en) | 2021-12-23 |
KR20230035043A (ko) | 2023-03-10 |
WO2021257595A1 (en) | 2021-12-23 |
JP2023530974A (ja) | 2023-07-20 |
IL299094A (en) | 2023-02-01 |
AU2021293197A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000156A2 (es) | Administración de vectores de virus adenoasociado para distrofias musculares | |
CO2019011250A2 (es) | Administración de vectores del virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular | |
CO2018012084A2 (es) | Administración de vectores del virus adenoasociado de microdistrofina para tratar la distrofia muscular | |
CO2021000227A2 (es) | Suministro mediante vectores de virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular | |
EA202091615A1 (ru) | Интраназальные составы на основе эпинефрина и способы лечения заболевания | |
CO2018012082A2 (es) | Administración de vectores del virus adenoasociado de β-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular | |
BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
WO2020123645A8 (en) | Combination therapy for treating muscular dystrophy | |
MX2021006751A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
BR112016022854A2 (pt) | método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene | |
CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
BR112022007721A2 (pt) | Método para o tratamento da demência | |
BR112018069727A2 (pt) | métodos de tratamento com vitamina d | |
CO2021003726A2 (es) | Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto | |
BR112023021999A2 (pt) | Administração de terapia gênica de microdistrofina para tratamento de distrofinopatias | |
AR105142A1 (es) | Métodos de tratamiento del glioblastoma multiforme con terapia de células t | |
AR118192A1 (es) | ADMINISTRACIÓN DE b-SARCOGLICANO CON UN VECTOR DE VIRUS ADENOASOCIADO Y TRATAMIENTO DE LA DISTROFIA MUSCULAR | |
AR122624A1 (es) | Administración del virus adenoasociado para las distrofias musculares | |
AR115563A1 (es) | Suministro de microdistrofina específica de músculo mediante vectores de virus adenoasociados para tratar la distrofia muscular | |
CO2023004031A2 (es) | Administración sistémica del vector de virus adenoasociado que expresa el sarcoglucano g y el tratamiento de la distrofia muscular | |
Ociepa | DRESS syndrome: case report | |
GR1008769B (el) | Οξινο διαλυμα αιμοκαθαρσης με l-ασκορβικο οξυ (βιταμινη c) | |
EA202192346A1 (ru) | Доставка -саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии |